Replimune to Acquire Remaining Shares

Ticker: REPL · Form: 8-K · Filed: 2025-09-18T00:00:00.000Z

Sentiment: neutral

Topics: acquisition, corporate-action

TL;DR

Replimune is buying out the rest of the company to simplify things and fund growth.

AI Summary

Replimune Group, Inc. announced on September 16, 2025, that it has entered into a definitive agreement to acquire all outstanding shares of the company not already owned by it. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions. This move aims to simplify Replimune's capital structure and enhance its ability to fund future growth.

Why It Matters

This acquisition simplifies Replimune's capital structure, potentially making it easier to fund future research and development efforts.

Risk Assessment

Risk Level: medium — Acquisitions carry inherent risks, including integration challenges and potential overpayment, which could impact future financial performance.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing is primarily to report on the definitive agreement for Replimune Group, Inc. to acquire all outstanding shares of the company not already owned by it, which is considered an 'Other Event' and a 'Regulation FD Disclosure'.

When is the expected closing date for the acquisition?

The acquisition is expected to close in the fourth quarter of 2025.

What is the stated goal of this acquisition for Replimune?

The stated goal is to simplify Replimune's capital structure and enhance its ability to fund future growth.

What are the conditions for the acquisition to close?

The acquisition is subject to customary closing conditions.

What is Replimune Group, Inc.'s principal executive office address?

Replimune Group, Inc.'s principal executive offices are located at 500 Unicorn Park Drive Suite 303 Woburn, MA 01801.

Filing Stats: 592 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2025-09-18 09:20:45

Key Financial Figures

Filing Documents

01 Regulation

Item 7.01 Regulation FD Disclosure . On September 18, 2025, Replimune Group, Inc. (the "Company") issued a news release announcing that it completed a Type A meeting with the U.S. Food and Drug Administration (the "FDA") on September 16, 2025 regarding the Company's Biologics License Application ("BLA") for RP1 in combination with nivolumab for the treatment of advanced melanoma. The Company is evaluating the feedback from the FDA provided during the meeting to determine next steps. A copy of such news release regarding this meeting is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly stated by specific reference in such filing.

01 Other

Item 8.01 Other Events . On September 16, 2025, the Company completed a Type A meeting with the FDA regarding the Company's BLA for RP1 in combination with nivolumab for the treatment of advanced melanoma.

01 Financial

Item 9.01 Financial Statements and Exhibits . Exhibit No. Description 99.1 News Release dated September 18, 2025 104 Cover page interactive data file (formatted as Inline XBRL)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REPLIMUNE GROUP, INC. Date: September 18, 2025 By: /s/ Sushil Patel Sushil Patel Chief Executive Officer

View on Read The Filing